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The effects of RU 486 combined with tamoxifen and tamoxifen
alone on hormonal parameters and endometrial development
at the time of implantation were studied. Measurements of
cytosolic oestrogen and progesterone receptors in endo-
metrium and placental protein 14 (PP14) in plasma were also
included. Three dosage schedules were used: single oral dose
of 40 mg tamoxifen alone and in combination with 200 mg
RU 486, and 40 mg tamoxifen for three consecutive days
starting on the first day after the luteinizing hormone (LH)
surge. The combined treatment prolonged the luteal phase
(P < 0.05) and increased the plasma levels of progesterone.
A single dose of tamoxifen did not affect the bleeding pattern
and plasma hormone levels, but raised plasma oestradiol and
LH with the 3-day treatment. The endometrium was retarded
after the combined and the 3-day treatment with tamoxifen.
Concentrations of cytosolic progesterone receptors were
higher after the combined therapy, but were unaffected after
tamoxifen only. PP14 levels were higher (P < 0.05) after
repeated tamoxifen doses than in controls, but were lower
with combined treatment. Progesterone and oestrogen are
evidently necessary for endometrial maturation during the
secretory phase of the menstrual cycle. PP14 levels in plasma
cannot be used for clinical assessments of endometrial function
because high levels coincide with disturbed endometrial
development.
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Introduction
Ovarian steroids are responsible for the development of a normal
endometrium during different phases of the menstrual cycle.
Oestradiol is essential for the synthesis of the progesterone
receptor, and progesterone down-regulates both the oestradiol
and the progesterone receptors (Janne et al., 1975; Tseng and
Gurpide, 1975; Kreitmann et al., 1979). Hence, treatment with
receptor blockers might interfere with the regulation of the
menstrual cycle by affecting both the hormonal balance and
endometrial development. In normally cychng women, treatment
with the progesterone receptor blocker RU 486 (Roussel, Uclaf,
Paris, France) in mid- to late luteal phase induces uterine
bleeding, followed in some women by a second bleeding at the
time of the expected menstruation. The underlying mechanism
is mainly a local effect on the endometrium (Hermann et al.,
1985; Schaison etal, 1985; Swahn et al, 1988). A marked
retardation of endometrial development was noticed up to at least
4 days after a single dose of 200 mg RU 486 administered on
the second day after the luteinzing hormone (LH) peak without
affecting the bleeding or hormonal pattern of the cycle (Swahn
et al., 1990). On the other hand, treatment of women with 40 mg
daily of the oestrogen receptor blocker, tamoxifen (ICI,
Macclesfield, UK), over the entire luteal phase markedly
increased the level of ovarian hormones (Swahn et al., 1989)
during the treatment period and also during the subsequent cycle,
whereas the cycle length was only marginally affected. In
contrast, short-term treatment in the early luteal phase in primates
both prolonged the cycle and decreased the fertility rates (Ravin-
dranath and Moudgal, 1987; Olive et al., 1990) without affecting
hormonal secretion, indicating local effects of tamoxifen on the
endometrial development.
From studies on in-vitro fertilization (TVF) it appears that the
window of endometrial receptivity in the human is restricted to
- 3 days (Navot etal., 1991). It is therefore possible that
compounds which interfere with endometrial maturation in the
secretory phase may be developed into effective contraceptive
methods. The aim of the present study was to evaluate the effect
of tamoxifen and tamoxifen in combination with RU 486 on
hormonal parameters, endometrial histology and the serum
placental protein 14 (PP14) concentration around the time of
implantation following administration of the compounds
immediately after the LH surge.
Materials and methods
A total of 24 regularly menstruating healthy volunteers with a
cycle length between 25 and 35 days for the last three cycles
before admission were recruited for the trial. None of the women
used an intra-uterine device (IUD) or oral contraceptive steroids.
The study consisted of one control, one treatment and one post-
treatment cycle. The volunteers were allocated to one of three
treatment schedules: group I received 40 mg tamoxifen as a single
oral dose at 8.00 p.m. on the day after the urinary LH peak;
group II was given 40 mg tamoxifen daily for 3 days starting
at the corresponding time of the cycle; and group IE was given
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40 mg tamoxifen and 200 mg RU 486 at 8.00 p.m. on cycle day
LH + 1 (single dose).
An endometrial biopsy was obtained from the fundal part of
the uterus on day LH + 7 both in the control and in the treatment
cycles. Part of the biopsy material was taken for morphometric
analysis by light microscopy (Johannisson etal., 1987). The
remaining material was snap frozen and studied for cytosolic,
progesterone and oestrogen receptors using enzyme immunoassay
(Abbott Laboratories, North Chicago, USA). In all patients urine
samples from the first morning void were collected daily from
day 7 of the cycle until the LH surge had been demonstrated in
the control and treatment cycles. The appearance of the LH surge
was identified using a dip-stick method (Ovukit, Monoclonal
Antibodies, Inc., Sunnyvale, CA, USA) and verified by analysis
of the morning urine samples by radioimmunoassay. Blood
samples were drawn three times weekly from the day the dip-
stick urine analysis indicated appearance of the LH peak until
menstruation in both cycles and analysed for LH, progesterone,
oestradiol and endometrial protein PP14. The pituitary and
ovarian hormones were measured by radioimmunoassay using
kits provided by the World Health Organization (WHO) Matched
Programme (Sufi et al., 1988). Serum concentrations of PP14
were determined by radioimmunoassay (Seppala et al., 1987).
During the three cycles of the study, the subjects were asked to
keep records on the duration and amount of vaginal bleeding and
side-effects of the drug regimen. During the study period, the
women were advised to use barrier methods for contraception.
The geometric mean and 95 % confidence limits were calculated
for the plasma levels of LH, ovarian steroids and PP14.
Progesterone and oestradiol values were normalized around the
day of the plasma LH surge. The area under the curve was
calculated for the period from the LH peak to day LH + 10 for
the ovarian hormones from day LH + 3 to day LH + 10 for
LH in plasma using the summation of the trapezoidal areas
between consecutive points. The area under the curve was used
when comparing the hormonal levels. The PP14 levels were
synchronized according to the first day of the following
menstruation and the area under the curve was calculated for the
last 10 days of the menstrual cycle including the first day of
bleeding.
A log normal distribution was assumed for all hormonal and
PP14 levels (Gaddum, 1945). For statistical calculations, paired
f-test and two-way analysis of variance with appropriate contrasts
were used, and a P-value <0.05 was considered statistically
significant.
The study was approved by the Swedish Drug Regulatory
Authorities and the Ethics Committee of the Karolinska Hospital.
Results
Effects on cycle length
The three treatment groups were similar with regard to age,
weight, height, previous number of pregnancies and births. Table
I illustrates the effect of different treatments on the duration of
the menstrual cycle. The combination of a single dose of RU
486 and tamoxifen (group HI) significantly prolonged the cycle
(P < 0.05), from 27.9 ± 3.0 (mean ± SD) in the control to
35.0 ± 10.5 days in the treatment cycle. However, in two
subjects the treatment cycle was prolonged to 42 and 56 days
respectively. After exclusion of these two subjects, the mean
duration of control and treatment cycles for the remaining subjects
was 27.0 ± 2.8 and 30.0 ± 3.0 days, respectively, this
difference still being statistically significant (P <0.05). Pro-
longation of the cycle was due to extension of the luteal phase
from 12.6 ± 1 . 8 days in the control to 14.7 ± 0.5 days in the
treatment cycle (P < 0.05). No effects were seen on the duration
of the menstrual cycle by the two other treatment regimens. No
other adverse reactions were registered by any of the participating
women.
Hormone levels
Measurement of the LH surge in urine with the quick-test method
and the radioimmunoassay gave similar results, while the plasma
LH peak appeared slightly earlier (mean 0.53 days; range - 1
to +2). In two subjects in treatment group II and in the two
subjects in treatment group m with markedly extended treatment
cycles, the discrepancy between plasma LH and that measured
in urine was more pronounced. These four subjects were excluded
from the statistical evaluation of hormone values. No differences
were seen in the mean plasma levels of LH, oestradiol and
progesterone during the control cycles when the three treatment
groups were compared (results not shown). After a single dose
of tamoxifen (group I), the levels of ovarian hormones and LH
did not differ from those of the control cycle. Treatment with
tamoxifen for 3 days (group II) induced a significant increase
in oestradiol levels (P < 0.01) (Figure 1), whereas progesterone
Table I. Mean (±SD) duration of menstrual cycle in the control, the treatment and the post-treatment cycle when 40 mg tamoxifen as a single dose (group
I), tamoxifen 40 mg daily for 3 days (group II) and tamoxifen 40 mg single dose plus RU 486 200 mg single dose (group US) were given or started (group U)
in the evening of the luteinizing hormone (LH) surge +1
Days (mean ± SD)
Control Treatment
Proliferative Luteal Total Proliferative Luteal Total
Post-treatment
Total
Group I (n = 8)
Group II (n = 8)
Group m (TI = 8)
Group m (n = 6)a
14.2 ± 2.2
15.7 ± 3.5
15.7 ± 2.6
14.8 ± 3.0
12.9 ± 2.7
11.7 ± 3.2
12.1 ± 1.6*
12.6 ± 1.8*
27.1 ± 3.1
27.5 ± 3.2
27.9 ± 3.0*
27.0 ± 2.8*
14.9 ± 3.0
16.2 ± 4.0
16.4 ± 3.1
15.3 ± 2.7
13.4 ± 1.5
13.7 ± 2.3
18.6 ± 8.1*
14.7 ± 0.5*
28.1 ± 2.4
31.2 ± 32.9
35.0 ± 10.5*
30.0 ± 3.0*
27.4 ± 3.4
27.7 ± 2.2
31.4 ± 8.4
T w o patients in whom the cycle length in the treatment cycle was prolonged to 42 and 56 days, respectively, have been excluded.
*Statistically significant difference between corresponding periods in the control and treatment cycles (P < 0.05).
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levels were unaffected (data not shown). LH levels were also
significantly increased (P < 0.01) (Figure 1). After the combined
therapy (group HI), progesterone levels were slightly but
significantly increased (P < 0.05), but the oestradiol (data not
shown) and LH levels remained unaffected (Figure 2). Table II
gives the area under the curve for plasma levels of progesterone,
oestradiol and LH.
Morphometric analysis
The results of the morphometric analyses are summarized in
Table HI. For treatment group I, the day of the biopsy varied
< 1 day when related to the urinary and plasma LH surges,
whereas in treatment groups II and IE, the day of biopsy differed
by > 3 days in four subjects (two in each group) when related
to the plasma LH surge.
Treatment with a single dose of tamoxifen (group I) had only
a marginal effect on the endometrial development. A slight
increase in the number of glands (24.7 ± 7.0, versus
21.7 ± 3.9 mm2) (P < 0.05) and a decrease of glandular
epithelial height (18.8 ± 1.5 versus 20.01 ± 1.1 /*m)
(P < 0.05) were observed. Treatment with tamoxifen for 3 days
(group II) considerably disturbed the endometrial morphology.
In only one subject was the endometrial development considered
in phase with the cycle, whereas irregular secretory activity or
a retarded endometrium was demonstrated in the remaining
subjects. In this group, statistical evaluation of the morphometric
analysis revealed a significant increase in the number of
vacuolated cells (525 versus 69/103 cells) (P < 0.01) and
decreased glandular diameter (83 ± 21 versus 102 ± 13 urn)
(P < 0.05). In treatment group HI, the morphometric anlaysis
was not conclusive in one subject in the treatment cycle. In the
remaining subjects, irregular secretory activity or slight
proliferation was noted in all but one subject, in whom the
morphology was well in phase with the cycle. Again, statistical
evaluation revealed increased numbers of glandular (P < 0.05)
and stromal (P < 0.001) mitoses and a decrease in glandular
diameter (P < 0.005) and glandular secretion (P < 0.01).
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Fig. 1. Plasma levels of luteinizing hormone and oestradiol during
control (group I) and treatment (group II) cycles after 40 mg of
tamoxifen from cycle day LH + 1 to +3 (geometric mean and
95% confidence limits) (n = 6).
Fig. 2. Plasma levels of luteinizing hormone and progesterone in
six subjects during control and treatment (group HI) cycles after a
single dose of 40 mg tamoxifen and 200 mg RU 486 (mifepristone)
on cycle day LH + 1 (geometric mean and 95% confidence limits).
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Table n . Area under the curve for plasma levels of progesterone, oestradiol, luteinizing hormone (LH) and placental protein 14 (PP14) for the three treatment
groups (specificed in Table I). The period calculated was day of the LH surge to LH + 10 for progesterone and oestradiol; LH + 3 to LH + 10 for LH and
the 10 last days of the cycle including the first day of bleeding for PP14
Group I (n = 8)
Control Treatment
Group II (n = 6)
Control P Treatment
Group m (n = 6)
Control Treatment
Progesterone
Oestradiol
LH
PPM
326
(275-387)
5668
(5028-6389)
18.7
(12.3-28.4)
254
(193-335)
NS
NS
NS
NS
316
(259-386)
6273
(5330-7383)
22.7
(16.2-31.8)
309
(238-402)
288
(198-419)
6226
(5084-7624)
18.6
(13.3-26.0)
251
(179-352)
NS
<0.01
<0.01
<0.05
382
(284-513)
7919
(6885-9109)
29.8
(20.4-43.6)
445
(179-711)
261
(213-319)
6392
(5173-7899)
30.9
(17.7-53.8)
230
(148-360)
<0.05
NS
NS
<0.01
328
(261 -413)
6781
(5336-8616)
56.4
(40.5-78.6)
171
(124-234)
NS = not significant.
Data are of geometric mean and 95% confidence limits.
Table m . Results of seven parameters assessed in the morphometric analysis of endometrial
combination with RU 486 (group HI) was administered in the very early luteal phase
Group I
(n = 8)
Control P
Group II
(71 = 6 )
Treatment Control P
development when
Treatment
tamoxifen alone
Group ID
(n = 6)
Control
(groups
P
I and II) or in
Treatment
No. of glands/mm2 21.7 ± 3.9 <0.05 24.7 ± 7.0g
No. of glandular mitoses/ 0
103 cells
No. of stromal mitoses/ 0.6(0-2)
103 cells
No. of vacuolated cells/ 21(0-100)
103 cells
Glandular diameter 0*m)
Glandular secretion
(score 0 - 3 )
Glandular epithelial
height Gun)
108 ± 18
2.5 ± 0.6
NS
NS
NS
NS
NS
0
0.2(0-0.5)
107(0-500)
89 ± 20
1.8 ± 0.5
20.0 ± 1.1 <0.05 18.8 ± 1.5
20.7 ± 7.0
0
0.7(0-3)
69(0-550)
102 ± 13
2.6 ± 0.8
20.5 ± 2.3
NS 18.7 ± 4.3
NS 2.0(0-12)
22.9 ± 6.5
0.7(0-4)
NS 1.9(0-7.3) 0.7(0-1.4)
NS 19.6 ± 7.8
<0.05 6.2(0-13.4)
<0.001 2.9(1.5-4.6)
<0.01 525(0-1000) 271(0-850) NS 193(0-550)
<0.05 83 ± 21
NS 2.0 ± 0.7
100 ± 11
2.3 ± 0.7
< 0.005 66 ± 22
<0.01 1.4 ± 0.4
NS 21.9 ± 2.9 20.2 ± 2.9 NS 20.2 ± 2.6
Values given are mean (range) and mean ± SD.
The specifications of the three treatment groups are given in Table I.
Table IV. Concentrations of progesterone and oestrogen receptors in endometrial biopsies on day of luteinizing hormone surge LH + 7 in control and
treatment cycles for the three treatment groups (specified in Table I)
Progesterone receptor (fmol/mg protein) Oestrogen receptor (fmol/mg protein)
Group I (TI =
Group n (TI =
Group Ha (TI =
Group HI (TI =
Group m a (TI
7)
= 7)
 5)
 6)
= 4)
Control
376 (265-524)
599 (501-716)
578 (477-699)
595 (410-863)
696 (409-1182)
P
NS
NS
NS
<0.05
NS
Treatment
433 (313-599)
643 (380-1089)
469 (352-624)
912 (715-1163)
967 (767-1219)
Control
59 (40-89)
78 (55-110)
81 (55-119)
91 (47-175)
122 (51-289)
P
NS
NS
NS
NS
NS
Treatment
69 (48-99)
74 (47-117)
59 (38-93)
148 (102-216)
154 (119-200)
T w o subjects with ovulatory disturbances in the treatment cycle are excluded.
Data are of geometric mean and 95 % confidence limits.
Steroid receptors
The concentration of cytosolic progesterone and oestrogen
receptors from a total of 20 subjects is shown in Table IV. The
levels of progesterone and oestrogen receptors were unaffected
by single or repeated doses (groups I and IT) of tamoxifen,
whereas the combined treatment (group DJ) increased the levels
of progesterone receptors (P < 0.05). However, this elevation
was not significant after exclusion of the two subjects with
ovulatory disturbances in the treatment cycle.
PPM
The plasma levels of PP14 were measured from the LH peak
to the onset of menstruation. In control cycles, the PP14
concentration was ~ 15 /*g/l during the first week following the
LH surge, but it increased steadily thereafter and reached
72 ± 28 /tg/1 (mean ± SD) on the first day of menstruation
(Figure 3A). After treatment with a single dose of tamoxifen
(group I) the plasma levels of PPM tended to be higher than
during the control cycle but the difference was not significant
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Fig. 3. Plasma levels of placental protein 14 (PP14) during control cycle (A), after a single dose of 40 mg tamoxifen on cycle day LH + 1
(B; group I, n = 8), 40 mg tamoxifen on cycle days LH + 1 to LH + 3 (C; group n, n = 6) and a single dose of 40 mg tamoxifen and
200 mg mifepristone on cycle day LH + 1 (D; group m, n = 6) (geometric mean and 95% confidence limits). Day 0 refers to the first
day of menstruation.
(Figure 3B). After 3 days' treatment with tamoxifen (group II)
the levels were significantly higher (P < 0.05) than during the
control cycle (Figure 3C). After the combined treatment (group
HI) the levels of PP14 were significantly lower (P < 0.01) than
the control cycle (Figure 3D). This finding was also valid after
exclusion of the two patients with prolonged cycles from the
analysis of data (Table II).
Discussion
The aim of the present study was to evaluate the effects of
antihormone treatment when administered early in the luteal
phase. The patients received either a single oral dose of 40 mg
tamoxifen (group I), 40 mg tamoxifen daily for 3 days (group
II) or a combination of 40 mg tamoxifen and 200 mg RU 486
(group IH). Tamoxifen is a derivative of triphenylethylene, which
is supposed to act through binding to the oestrogen receptor. It
is generally agreed that the antagonistic effect dominates over
the oestrogenic action (Furr and Jordan, 1984). RU 486 similarly
interacts with the progesterone receptor but has almost entirely
antagonistic effects (Philibert et al., 1985). The half-life of both
tamoxifen and RU 486 is long; for tamoxifen it is 7.5 days (Furr
and Jordan, 1984) and for RU 486 detectable plasma levels have
been demonstrated up to one week after a single oral dose of
200 mg in most subjects (Swahn etal, 1990).
Bleeding pattern, hormone levels in blood and urine,
endometrial development and concentration of oestrogen and
progesterone receptors were monitored. Plasma hormone levels
were measured three times a week and therefore, in some
subjects, the concentration during the last day or two of the luteal
phase was not available. Hormone levels were presented as the
area under the curve during the time hormone levels were known
for all patients. The treatment was invariably given at or started
at 8.00 p.m. on the first day after the urinary LH surge. In most
cases the urinary LH surge detected by the quicktest method
coincided with the plasma LH surge. As follicular rupture occurs
within 24 h after the start of the plasma LH surge (Garcia et al.,
1981), the treatment was initiated after rupture of the dominant
follicle. In two patients in each of treatment groups II and HI
there was a significant discrepancy in the time between the plasma
and urinary LH peaks. Since incorrect timing of the treatment
was possible in these cases, and effects of antihormones are
dependent on the timing of the treatment, these subjects were
excluded when plasma levels of ovarian steroids were calculated.
A single dose of tamoxifen in contrast to 3 days' treatment
did not affect the menstrual cycle or any of the parameters
assessed. This may indicate that the role of oestrogen in the early
stage of the luteal phase is less important than in later stages,
but could also be due to the increase in total dose of tamoxifen
administered.
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Both tamoxifen (Sgarlata et al., 1984) and RU 486 (DiMattina
et al., 1987) inhibit progesterone production in human granulosa
cells in vitro. However in the present study, a single dose of
tamoxifen administered immediately after ovulation did not
interfere with luteal function judged by progesterone levels in
plasma. A similar finding has been made after treatment with
RU 486 alone in the early luteal phase (Swahn et al., 1990). Even
repeated treatment with tamoxifen was without effect in this
respect, confirming the previous results of Sherman et al. (1979).
The principal effect of tamoxifen and RU 486 given together was
apparently a stimulation of the corpus luteum function. The
plasma progesterone levels were elevated concomitantly with a
prolongation of the luteal phase. Similar effects have also been
reported after antigestagen and tamoxifen treatment alone in later
stages of the luteal phase (Garzo et al., 1988; Swahn et al.,
1988). The luteotrophic effect of the combined therapy may
reflect the effects at hypothalamic-pituitary level, although mean
LH levels were not increased. However, the increased levels of
progesterone receptor concentration of the endometrium may
have potentiated the effects of increased progesterone levels on
the uterus, postponing endometrial desquamation.
It is now well established that the formation of progesterone
and oestrogen receptors is regulated by ovarian steroid hormones.
We measured the effect of the antihormones tamoxifen and RU
486 on the concentration of both oestrogen and progesterone
receptors in the endometrium. When interpreting the results, we
appreciate that tamoxifen has some steroid agonistic effects.
Short-term therapy with tamoxifen reduces the cytosolic oestrogen
receptor concentration in the endometrium, while the
progesterone receptor concentration actually increases (Baulieu
et al, 1981), effects that are consistent with both antagonistic
and agonistic activities. Although RU 486 is regarded as an almost
pure antigestagen, secretory changes have been described in the
endometrium of post-menopausal women pre-treated with
oestrogen alone (Gravanis et al., 1985).
In the present study, neither of the tamoxifen treatment
schedules were found to induce durable effects on endometrial
steroid receptor levels. However, the time elapsed from the end
of treatment to biopsy may have been too long to reveal early
transitory changes in receptor concentrations. Increased levels
of total oestrogen receptors but lack of effect on progesterone
receptors have recently been reported by Gorodeski et al. (1992)
after a single dose of tamoxifen in mid-luteal phase. Differences
in treatment timing may explain the divergence between our
results and those of Gorodeski et al. (1992). Also, in the present
study, only cytosolic receptors were analysed and unknown
amounts of nuclear receptors may thus have escaped analysis.
The combined therapy with antigestagen and anti-oestrogen
significantly increased progesterone receptor concentrations
whereas oestrogen receptor concentration was only slightly, but
not significantly, elevated. These findings are consistent with the
antagonistic effects of RU 486. The previously reported transitory
decrease in progesterone receptor concentrations following
administration of RU 486 early in luteal phase (Swahn et al.,
1990) may have reflected some agonistic effects of RU 486 due
to insufficient gestagenic activity at this early stage of the luteal
phase. The addition of the oestrogen receptor blocker in the
present study may have increased the antagonistic potency of RU
486 on the endometrium and, in fact, anti-oestrogens have been
reported to exert some secretory changes in proliferative
endometrium (Birkenfeld et al., 1986).
The disturbance of endometrial maturation seen after repeated
doses of tamoxifen could be attributed to either an influence on
progesterone or oestrogen receptors by the anti-estrogen, or to
the increased levels of oestradiol in plasma, or to both. Delayed
maturation of luteal phase endometrium has been reported earlier,
both following continuous treatment with tamoxifen during the
whole cycle (Sherman et al., 1979) and also in the luteal phase
(Fritz etal, 1987). The high number of vacuolated cells
contradicts any major effects on progesterone receptor function
as this is mainly a progesterone-mediated effect. Since tamoxifen
has a long half-life (7.5 days), substantial amounts of tamoxifen
would still have been present at the time of biopsy and, therefore,
the influence of elevated oestradiol levels on endometrium is
unlikely. A blockage of oestrogen receptors during undisturbed
progesterone influence seems to be the probable explanation for
the endometrial structure observed following tamoxifen therapy,
i.e., small glands, persistence of basal vacuoles and an abnormal
secretion. Thus, not only progesterone but also oestrogen is
essential for the maturation of the endometrium during the
secretory phase.
Following the effects of combined tamoxifen—RU 486
treatment clearly indicates that the development of secretory
endometrium was inhibited. This was seen despite elevated levels
of both progesterone receptor in the endometrium and
progesterone in plasma indicating a persistent blockage of
progesterone receptors by RU 486 on day LH + 7. It is note-
worthy that if RU 486 administration starts in the mid-luteal
phase, the therapy invariably results in bleeding (Swahn et al.,
1988). On the other hand, if RU 486 is given immediately after
ovulation, bleeding is only rarely induced in spite of the fact that
RU 486 is still present in the circulation and its antagonistic effect
can be demonstrated on day LH + 7 (Swahn et al., 1990). This
finding indicates that some secretory development is a prerequisite
for endometrial shedding and bleeding to be induced by RU 486.
In spite of the receptor blockage seen on day LH + 7, an overtly
normal menstruation followed. This indicates that the process
is reversible. Reversible effects of RU 486 on glandular secretion
and uteroglobin production of the endometrium of pseudo-
pregnant rabbits have also been reported (Hegele-Hartung and
Beier, 1986).
Endometrial protein PP14 is synthesized by endometrial
secretory glands (Julkunen etal., 1990). The plasma
concentration of PP14 shows cyclic variation, being maximal at
the onset of menstruation (Julkunen et al., 1986). Due to this
pattern of PPM secretion in plasma in the present study, the
plasma levels of PP14 were synchronized around the first day
of the menstruation and the area under the curve calculated for
the last 10 days of the cycle, the period when progesterone levels
were elevated. RU 486 rather than tamoxifen decreased serum
PP14 levels, a finding confirming the belief that progesterone
elevates PP14. Following combined therapy, glandular diameter
and secretion decreased. Perhaps as a direct cause of the
decreased PP14 (Julkunen etal., 1990). Repeated tamoxifen
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treatment significantly elevated levels of PP14 associated with
increased glandular secretion without concomitant increase in
progesterone concentration. This indicates that not only
progesterone but also oestrogen, or the balance between these
two, is important for the production of PPM. PP14 may help
to assess endometrial function at the end of the menstrual cycle
(Fay etal, 1990), but the present study shows that PP14
concentrations are high when endometrial development is highly
deranged.
It is concluded that a single dose of tamoxifen given in
combination with RU 486 on day LH + 1 has a strong influence
on endometrial development. It significantly depresses the
production of endometrial protein PP14, leaving the plasma levels
of oestradiol and LH unchanged, and causing a slight increase
in progesterone during the secretory phase. It is not known
whether these effects are sufficient to prevent implantation.
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